Moderna's Financial Performance and Outlook for 2024 Revenue
Thursday, 2 May 2024, 10:35
Moderna's Financial Performance:
The latest earnings report from Moderna indicates a stronger financial position than anticipated, with a notable focus on Covid vaccine sales.
Outlook for 2024 Revenue:
The company is confident in achieving its full-year 2024 sales guidance of nearly $4 billion, attributing it to the anticipated revenue from the upcoming launch of the RSV vaccine.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.